GB2510477B - Formulations for use in the treatment of chronic fatigue and associated conditions, etc - Google Patents

Formulations for use in the treatment of chronic fatigue and associated conditions, etc

Info

Publication number
GB2510477B
GB2510477B GB1321945.6A GB201321945A GB2510477B GB 2510477 B GB2510477 B GB 2510477B GB 201321945 A GB201321945 A GB 201321945A GB 2510477 B GB2510477 B GB 2510477B
Authority
GB
United Kingdom
Prior art keywords
formulations
treatment
chronic fatigue
associated conditions
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1321945.6A
Other versions
GB2510477A (en
GB201321945D0 (en
Inventor
Francis Bennett Christopher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB201321945D0 publication Critical patent/GB201321945D0/en
Publication of GB2510477A publication Critical patent/GB2510477A/en
Application granted granted Critical
Publication of GB2510477B publication Critical patent/GB2510477B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
GB1321945.6A 2013-01-31 2013-12-11 Formulations for use in the treatment of chronic fatigue and associated conditions, etc Expired - Fee Related GB2510477B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1301771.0A GB2510374A (en) 2013-01-31 2013-01-31 Formulation comprising N-acetylcarnitine and D-ribose

Publications (3)

Publication Number Publication Date
GB201321945D0 GB201321945D0 (en) 2014-01-22
GB2510477A GB2510477A (en) 2014-08-06
GB2510477B true GB2510477B (en) 2017-12-13

Family

ID=47988520

Family Applications (2)

Application Number Title Priority Date Filing Date
GB1301771.0A Withdrawn GB2510374A (en) 2013-01-31 2013-01-31 Formulation comprising N-acetylcarnitine and D-ribose
GB1321945.6A Expired - Fee Related GB2510477B (en) 2013-01-31 2013-12-11 Formulations for use in the treatment of chronic fatigue and associated conditions, etc

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB1301771.0A Withdrawn GB2510374A (en) 2013-01-31 2013-01-31 Formulation comprising N-acetylcarnitine and D-ribose

Country Status (1)

Country Link
GB (2) GB2510374A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120731A1 (en) * 2016-01-11 2017-07-20 Shanghai Yao Yuan Biotechnology Co., Ltd. Methods and compositions for reducing body weight
CN114208971B (en) * 2021-11-29 2023-06-09 中国科学院水生生物研究所 Application of D-ribose in feed for improving flavor and meat quality of crucian

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095915A1 (en) * 2000-06-14 2001-12-20 Sigma-Tau Healthscience S.P.A. Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose
WO2003049687A2 (en) * 2001-12-06 2003-06-19 Weller Health, Inc. Medicinal compositions & therapeutic methods
US20040241256A1 (en) * 2002-12-05 2004-12-02 Seymour Ehrenpreis Medicinal compositions & therapeutic methods
WO2005089774A1 (en) * 2004-03-18 2005-09-29 Tanabe Seiyaku Co., Ltd. D-ribose for improving depression-like symptoms
US20080319076A1 (en) * 2008-09-02 2008-12-25 Bruce Kneller Compositions comprising creatine salts and methods of use thereof
US20130059038A1 (en) * 2011-09-01 2013-03-07 John C. Gilkey Nutritional composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022052A1 (en) * 2000-04-06 2002-02-21 Dransfield Charles William Transdermal delivery system
US20080233245A1 (en) * 2007-03-19 2008-09-25 Lesley Joan White Liquid nutrient composition for improving performance
TW201201712A (en) * 2010-01-28 2012-01-16 Max International Llc Compositions comprising sugar-cysteine products

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095915A1 (en) * 2000-06-14 2001-12-20 Sigma-Tau Healthscience S.P.A. Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose
WO2003049687A2 (en) * 2001-12-06 2003-06-19 Weller Health, Inc. Medicinal compositions & therapeutic methods
US20040241256A1 (en) * 2002-12-05 2004-12-02 Seymour Ehrenpreis Medicinal compositions & therapeutic methods
WO2005089774A1 (en) * 2004-03-18 2005-09-29 Tanabe Seiyaku Co., Ltd. D-ribose for improving depression-like symptoms
US20080319076A1 (en) * 2008-09-02 2008-12-25 Bruce Kneller Compositions comprising creatine salts and methods of use thereof
US20130059038A1 (en) * 2011-09-01 2013-03-07 John C. Gilkey Nutritional composition

Also Published As

Publication number Publication date
GB2510477A (en) 2014-08-06
GB201321945D0 (en) 2014-01-22
GB2510374A (en) 2014-08-06
GB201301771D0 (en) 2013-03-20

Similar Documents

Publication Publication Date Title
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
HK1216251A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
PL3157512T3 (en) Use of cannabidiol in the treatment of epilepsy
HK1222778A1 (en) Medical device, and the methods of using same
GB201319621D0 (en) Antimicrobial agents and their use in therapy
PL3065759T3 (en) Immunosuppressive agents and their use in therapy
PL3004112T3 (en) Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
EP2976091C0 (en) Antioxidatively active composition and the use thereof
IL246855A0 (en) Agents for use in the treatment of retinal inflammation
EP3007834A4 (en) Device for, or in, the surface treatment of objects
IL251840A0 (en) Use of pemirolast in the treatment of acute asthma
PT2980096T (en) 2 ,3 ,5 -trihydroxy-androst-6-one and preparation methods and use thereof
GB2510477B (en) Formulations for use in the treatment of chronic fatigue and associated conditions, etc
GB201308753D0 (en) Compounds and their use in therapy
PT2862576T (en) Microorganisms and compositions comprising them for use in the treatment or prevention of mastitis
HK1209033A1 (en) Use of odiparcil in the treatment of mucopolysaccharidosis
GB201304038D0 (en) Treated cells and therapeutic uses
GB2540931B (en) Improvements in or relating to beauty treatments
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
GB201308217D0 (en) Compounds and their use in therapy
GB201415915D0 (en) Improvements in and Relating to ophthalmoscopes
GB201312131D0 (en) Drug combination and its use in therapy
GB201312129D0 (en) Drug combination and its use in therapy
GB201312128D0 (en) Drug combination and its use in therapy

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20181211